Based on Phase 2 clinical trial data published in the New England Journal of Medicine (2023), retatrutide shares a side-effect profile broadly consistent with other GLP-1 receptor agonist class medicines, though the addition of glucagon receptor agonism may introduce some distinct effects
Initially developed for type 2 diabetes, they are now recognized for their broad impact on weight regulation, inflammation, cardiovascular health, and neuroprotectiondomains central to longevity and healthy aging
No fasting, no water limit, no waiting around
They enhance regulatory T-cell function, which is significant because defective T-cell regulation is a core driver of autoimmune thyroid destruction
If you take a GLP-1 medication and notice sudden vision changes, do not wait to see if it improves
Natural human GLP-1 exists primarily as GLP-1(7-36) amide, a peptide that is rapidly degraded by DPP-4, resulting in a half-life of only 2 to 3 minutes